Table 2. Design of 265 interventional COVID-19 clinical trials.
| Variables | No (%) (n = 265) |
|---|---|
| Allocation | |
| Randomized | 157 (59.2) |
| Non-randomized | 108 (40.8) |
| Blinding | |
| Open-label | 247 (93.2) |
| Single-blind | 5 (1.9) |
| Double-blind | 12 (4.5) |
| Triple-blind | 1 (0.4) |
| Type of participants | |
| Confirmed case | 78 (29.4) |
| Common case | 31 (11.7) |
| Wild case /common case | 30 (11.3) |
| Wild case /severe case | 24 (9.1) |
| Severe case | 19 (7.2) |
| Severe case /critical case | 18 (6.8) |
| Common/severe case | 16 (6.0) |
| Rehabilitation case | 11(4.2) |
| Critical/suspected case | 9 (3.4) |
| Wild case | 9 (3.4) |
| Suspected/confirmed case | 8 (3.0) |
| Suspected case | 7 (2.6) |
| Healthy people | 5 (1.9) |
| Number of primary outcomes | |
| 1 | 175 (66.0) |
| 2–5 | 73 (27.5) |
| 6–9 | 15 (5.7) |
| >10 | 2 (0.8) |